Reaction Details |
| Report a problem with these data |
Target | Serine/threonine-protein kinase Chk2 |
---|
Ligand | BDBM27344 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_653796 (CHEMBL1226918) |
---|
IC50 | 1100±n/a nM |
---|
Citation | Montagnoli, A; Valsasina, B; Croci, V; Menichincheri, M; Rainoldi, S; Marchesi, V; Tibolla, M; Tenca, P; Brotherton, D; Albanese, C; Patton, V; Alzani, R; Ciavolella, A; Sola, F; Molinari, A; Volpi, D; Avanzi, N; Fiorentini, F; Cattoni, M; Healy, S; Ballinari, D; Pesenti, E; Isacchi, A; Moll, J; Bensimon, A; Vanotti, E; Santocanale, C A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol4:357-65 (2008) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Serine/threonine-protein kinase Chk2 |
---|
Name: | Serine/threonine-protein kinase Chk2 |
Synonyms: | CDS1 | CHEK2 | CHK2 | CHK2_HUMAN | Checkpoint Kinase (Chk2) | RAD53 | Serine/threonine-protein kinase Chek2 | Serine/threonine-protein kinase Chk1/2 |
Type: | Protein |
Mol. Mass.: | 60908.59 |
Organism: | Homo sapiens (Human) |
Description: | O96017 |
Residue: | 543 |
Sequence: | MSRESDVEAQQSHGSSACSQPHGSVTQSQGSSSQSQGISSSSTSTMPNSSQSSHSSSGTL
SSLETVSTQELYSIPEDQEPEDQEPEEPTPAPWARLWALQDGFANLECVNDNYWFGRDKS
CEYCFDEPLLKRTDKYRTYSKKHFRIFREVGPKNSYIAYIEDHSGNGTFVNTELVGKGKR
RPLNNNSEIALSLSRNKVFVFFDLTVDDQSVYPKALRDEYIMSKTLGSGACGEVKLAFER
KTCKKVAIKIISKRKFAIGSAREADPALNVETEIEILKKLNHPCIIKIKNFFDAEDYYIV
LELMEGGELFDKVVGNKRLKEATCKLYFYQMLLAVQYLHENGIIHRDLKPENVLLSSQEE
DCLIKITDFGHSKILGETSLMRTLCGTPTYLAPEVLVSVGTAGYNRAVDCWSLGVILFIC
LSGYPPFSEHRTQVSLKDQITSGKYNFIPEVWAEVSEKALDLVKKLLVVDPKARFTTEEA
LRHPWLQDEDMKRKFQDLLSEENESTALPQVLAQPSTSRKRPREGEAEGAETTKRPAVCA
AVL
|
|
|
BDBM27344 |
---|
n/a |
---|
Name | BDBM27344 |
Synonyms: | 2-(pyridin-4-yl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one | JMC502647 Compound 8 | Pyrrolopyridinone, 1 |
Type | Small organic molecule |
Emp. Form. | C12H11N3O |
Mol. Mass. | 213.2352 |
SMILES | O=C1NCCc2[nH]c(cc12)-c1ccncc1 |
Structure |
|